|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's Range||30.33 - 31.41|
|52 Week Range||17.20 - 32.31|
|Beta (5Y Monthly)||1.20|
|PE Ratio (TTM)||13.11|
|Earnings Date||May 03, 2021 - May 07, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||34.50|
U.S. regulators have approved the first new drug in over a decade for children with ADHD, which causes inattention, hyperactivity and impulsivity.
On Friday afternoon, Supernus Pharmaceuticals (NASDAQ: SUPN) announced that the U.S. Food and Drug Administration (FDA) had approved Qelbree for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients between the ages of 6 to 17. As a result of this regulatory update, shares of the biopharmaceutical company are rising sharply on Monday and were up by 10.2% as of 1:49 p.m. EDT after jumping by as much as 11.4% earlier in the day. It hasn't been an easy road for Supernus Pharmaceuticals' attempt to earn approval for Qelbree: The company conducted four phase 3 clinical trials with over 1,000 ADHD patients to demonstrate the safety and efficacy of this medicine.
Supernus (SUPN) gets FDA approval for ADHD treatment, Qelbree, in pediatric patients 6 to 17 years of age.